Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors.
Journal
Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
12
12
2018
revised:
10
01
2019
accepted:
12
01
2019
pubmed:
23
1
2019
medline:
14
6
2019
entrez:
23
1
2019
Statut:
ppublish
Résumé
To characterize demographic features, clinical characteristics, and oncologic outcomes of mesothelioma of the testis. A population based search was performed using the National Cancer Institute's SEER 18 database. Patients diagnosed with malignant mesothelioma of the male genital organs from 1973 to 2015 were identified. Data on patient age, race, tumor laterality, histologic subtype, tumor extent, tumor size, tumor grade, treatment, cause of death, and survival months was collected. Primary outcomes were overall survival (OS) and disease-specific survival (DSS). A total of 113 patients with testicular mesothelioma were identified. The 5-year OS and DSS for all patients was 49% and 58%, and the 10-year OS and DSS was 33% and 45%, respectively. Biphasic mesotheliomas were associated with worse OS compared to general mesotheliomas and epithelioid subtypes (P = .043 and P = .039, respectively). Median survival time was not reached in patients with T1 disease while OS was 1.7 years and DSS was 1.8 years for patients with T4 disease (OS P = .002, DSS P <.001). Tumors greater than or equal to 4 cm were associated with worse OS and DSS (OS P = .025, DSS P = .047). This rare malignancy has significant mortality, with poor survival associated with biphasic subtypes, higher disease stage, and a critical tumor size cutoff of 4 cm.
Identifiants
pubmed: 30668959
pii: S0090-4295(19)30064-0
doi: 10.1016/j.urology.2019.01.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-144Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.